Gustave Roussy Cancer Campus, Villejuif, France; INSERM U1015, Villejuif, France; Université Paris Sud-XI, Faculté de Médecine, Le Kremlin Bicêtre, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.
Gustave Roussy Cancer Campus, Villejuif, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France; Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U 1138, Paris, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
Immunity. 2014 Sep 18;41(3):345-347. doi: 10.1016/j.immuni.2014.09.001.
Transforming growth factor β (TGF-β) is a canonical immunosuppressive cytokine secreted by tumors. In this issue of Immunity, Stephen et al. (2014) reveal that tumor-derived TGF-β deactivates antitumor CD8(+) T cell responses through T cell upregulation of the FoxP1 transcription factor.
转化生长因子 β（TGF-β）是一种肿瘤分泌的经典免疫抑制细胞因子。在本期《免疫》中，Stephen 等人（2014 年）揭示，肿瘤衍生的 TGF-β 通过上调 FoxP1 转录因子使肿瘤杀伤性 CD8(+)T 细胞应答失活。
